CA2590261C - Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions - Google Patents
Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions Download PDFInfo
- Publication number
- CA2590261C CA2590261C CA2590261A CA2590261A CA2590261C CA 2590261 C CA2590261 C CA 2590261C CA 2590261 A CA2590261 A CA 2590261A CA 2590261 A CA2590261 A CA 2590261A CA 2590261 C CA2590261 C CA 2590261C
- Authority
- CA
- Canada
- Prior art keywords
- heterocyclyl
- optionally substituted
- alkyl optionally
- aryl
- nr4r5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 44
- 108010041788 rho-Associated Kinases Proteins 0.000 title claims abstract description 26
- 102000000568 rho-Associated Kinases Human genes 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 230000001404 mediated effect Effects 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical class NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 title abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 124
- 150000001875 compounds Chemical class 0.000 claims description 118
- 125000003118 aryl group Chemical group 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 206010030043 Ocular hypertension Diseases 0.000 claims description 9
- 206010067013 Normal tension glaucoma Diseases 0.000 claims description 8
- 230000008602 contraction Effects 0.000 claims description 8
- 201000002978 low tension glaucoma Diseases 0.000 claims description 8
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims description 7
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 7
- 230000003547 miosis Effects 0.000 claims description 7
- 239000003604 miotic agent Substances 0.000 claims description 7
- 150000003180 prostaglandins Chemical class 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000004090 neuroprotective agent Substances 0.000 claims description 6
- 230000003836 peripheral circulation Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 193
- 208000030533 eye disease Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 672
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 258
- 239000000047 product Substances 0.000 description 148
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 136
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 128
- 238000005160 1H NMR spectroscopy Methods 0.000 description 110
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 239000007787 solid Substances 0.000 description 92
- 238000000746 purification Methods 0.000 description 89
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 85
- 238000004440 column chromatography Methods 0.000 description 85
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 80
- 101150041968 CDC13 gene Proteins 0.000 description 68
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 68
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 67
- 239000003921 oil Substances 0.000 description 58
- 235000019198 oils Nutrition 0.000 description 58
- 238000004128 high performance liquid chromatography Methods 0.000 description 57
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 49
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 42
- 239000000908 ammonium hydroxide Substances 0.000 description 42
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- CAFSXVAFGILCCI-UHFFFAOYSA-N pyrazine-2,3-diamine Chemical compound NC1=NC=CN=C1N CAFSXVAFGILCCI-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 29
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 235000011152 sodium sulphate Nutrition 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 16
- 239000012458 free base Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000003590 rho kinase inhibitor Substances 0.000 description 14
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000001665 trituration Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- -1 bicyclic 4-aminopyrimidine analogs Chemical class 0.000 description 12
- 150000003840 hydrochlorides Chemical class 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 229910000080 stannane Inorganic materials 0.000 description 10
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 9
- 125000001931 aliphatic group Chemical group 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- VLPBEKHOQWMYTR-UHFFFAOYSA-N 2,3-dibromopyrazine Chemical compound BrC1=NC=CN=C1Br VLPBEKHOQWMYTR-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 7
- KJIODOACRIRBPB-UHFFFAOYSA-N 4-bromo-1h-indazole Chemical compound BrC1=CC=CC2=C1C=NN2 KJIODOACRIRBPB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 150000001499 aryl bromides Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 5
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940124274 edetate disodium Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- DJTRGKVPLFKUOC-UHFFFAOYSA-N 2-[(6-bromoindazol-2-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=CC(Br)=CC2=NN(COCC[Si](C)(C)C)C=C21 DJTRGKVPLFKUOC-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004382 visual function Effects 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RPTUTKUGFWIUAQ-UHFFFAOYSA-N 2-[(6-bromoindazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=C(Br)C=C2N(COCC[Si](C)(C)C)N=CC2=C1 RPTUTKUGFWIUAQ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HTKXRTUKPXEALT-UHFFFAOYSA-N 3-bromo-2h-indazole Chemical compound C1=CC=CC2=C(Br)NN=C21 HTKXRTUKPXEALT-UHFFFAOYSA-N 0.000 description 2
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000005347 biaryls Chemical group 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 150000002473 indoazoles Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 150000003216 pyrazines Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical group C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- KSERCJHSQPNSJM-UHFFFAOYSA-N (3-methylpyridin-4-yl)boronic acid Chemical compound CC1=CN=CC=C1B(O)O KSERCJHSQPNSJM-UHFFFAOYSA-N 0.000 description 1
- RDOPJBLTFCNOMO-UHFFFAOYSA-N 1-(3,5-dibromopyrazin-2-yl)azepane Chemical compound BrC1=NC(Br)=CN=C1N1CCCCCC1 RDOPJBLTFCNOMO-UHFFFAOYSA-N 0.000 description 1
- SVMIZCWMJJQYPS-UHFFFAOYSA-N 1-(3-amino-6-bromopyrazin-2-yl)piperidin-4-ol Chemical compound NC1=NC=C(Br)N=C1N1CCC(O)CC1 SVMIZCWMJJQYPS-UHFFFAOYSA-N 0.000 description 1
- JZDGIYPYMLESSD-UHFFFAOYSA-N 1-(3-amino-6-pyridin-4-ylpyrazin-2-yl)piperidin-4-ol Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1N1CCC(O)CC1 JZDGIYPYMLESSD-UHFFFAOYSA-N 0.000 description 1
- WUTHURZYORKZNV-UHFFFAOYSA-N 1-(6-bromo-3-piperidin-1-ylpyrazin-2-yl)-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=NC(Br)=CN=C1N1CCCCC1 WUTHURZYORKZNV-UHFFFAOYSA-N 0.000 description 1
- YYZMWQLBOJYSFJ-UHFFFAOYSA-N 1-(6-bromo-3-pyrrolidin-1-ylpyrazin-2-yl)-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=NC(Br)=CN=C1N1CCCC1 YYZMWQLBOJYSFJ-UHFFFAOYSA-N 0.000 description 1
- WWYQNMLOOCTHJD-UHFFFAOYSA-N 1-(6-pyridin-4-yl-3-pyrrolidin-1-ylpyrazin-2-yl)-1,4-diazepane;hydrochloride Chemical compound Cl.C1CCCN1C1=NC=C(C=2C=CN=CC=2)N=C1N1CCNCCC1 WWYQNMLOOCTHJD-UHFFFAOYSA-N 0.000 description 1
- WIWSZPBNALINQW-UHFFFAOYSA-N 1-[3-(azepan-1-yl)-6-bromopyrazin-2-yl]-4-methyl-1,4-diazepane Chemical compound C1CN(C)CCCN1C1=NC(Br)=CN=C1N1CCCCCC1 WIWSZPBNALINQW-UHFFFAOYSA-N 0.000 description 1
- LKIUWNPNMPXCQF-UHFFFAOYSA-N 1-[3-(azepan-1-yl)-6-pyridin-4-ylpyrazin-2-yl]-4-methyl-1,4-diazepane;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1N1CCCCCC1 LKIUWNPNMPXCQF-UHFFFAOYSA-N 0.000 description 1
- MHVSMFDBVMPRGT-UHFFFAOYSA-N 1-methoxyethanamine Chemical compound COC(C)N MHVSMFDBVMPRGT-UHFFFAOYSA-N 0.000 description 1
- WKYZYHKRRXPGBE-UHFFFAOYSA-N 1-methyl-4-(3-piperidin-1-yl-6-pyridin-4-ylpyrazin-2-yl)-1,4-diazepane;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1N1CCCCC1 WKYZYHKRRXPGBE-UHFFFAOYSA-N 0.000 description 1
- XDLZYRNKKMBYBH-UHFFFAOYSA-N 1-methyl-4-(6-pyridin-4-yl-3-pyrrolidin-1-ylpyrazin-2-yl)-1,4-diazepane;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1N1CCCC1 XDLZYRNKKMBYBH-UHFFFAOYSA-N 0.000 description 1
- ALZRYURNSVYEKA-UHFFFAOYSA-N 1-pyrazin-2-ylazepane Chemical compound C1CCCCCN1C1=CN=CC=N1 ALZRYURNSVYEKA-UHFFFAOYSA-N 0.000 description 1
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 1
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
- SMHOMFGFMJZEMW-UHFFFAOYSA-N 2-(pyrazin-2-ylamino)ethanol Chemical compound OCCNC1=CN=CC=N1 SMHOMFGFMJZEMW-UHFFFAOYSA-N 0.000 description 1
- FBMGFCWSHPUQCC-UHFFFAOYSA-N 2-[(3,5-dibromopyrazin-2-yl)amino]ethanol Chemical compound OCCNC1=NC=C(Br)N=C1Br FBMGFCWSHPUQCC-UHFFFAOYSA-N 0.000 description 1
- HMXGMSPABUNUOY-UHFFFAOYSA-N 2-[(3-amino-6-bromopyrazin-2-yl)-(2-hydroxyethyl)amino]ethanol Chemical compound NC1=NC=C(Br)N=C1N(CCO)CCO HMXGMSPABUNUOY-UHFFFAOYSA-N 0.000 description 1
- AEHJGXAWYULAJO-UHFFFAOYSA-N 2-[(3-amino-6-pyridin-4-ylpyrazin-2-yl)-(2-hydroxyethyl)amino]ethanol Chemical compound N1=C(N(CCO)CCO)C(N)=NC=C1C1=CC=NC=C1 AEHJGXAWYULAJO-UHFFFAOYSA-N 0.000 description 1
- SDBGBQSQKWGACK-UHFFFAOYSA-N 2-[(5-bromoindazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound BrC1=CC=C2N(COCC[Si](C)(C)C)N=CC2=C1 SDBGBQSQKWGACK-UHFFFAOYSA-N 0.000 description 1
- FVQBELOHFWLJGP-UHFFFAOYSA-N 2-[(5-bromoindazol-2-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=C(Br)C=CC2=NN(COCC[Si](C)(C)C)C=C21 FVQBELOHFWLJGP-UHFFFAOYSA-N 0.000 description 1
- YMVYNXUKIKJUJD-UHFFFAOYSA-N 2-[(6-bromo-2,3-dihydroindazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=C(Br)C=C2N(COCC[Si](C)(C)C)NCC2=C1 YMVYNXUKIKJUJD-UHFFFAOYSA-N 0.000 description 1
- GPULXZQVVPPHHI-UHFFFAOYSA-N 2-[4-(6-bromo-3-pyrrolidin-1-ylpyrazin-2-yl)piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C1=NC(Br)=CN=C1N1CCCC1 GPULXZQVVPPHHI-UHFFFAOYSA-N 0.000 description 1
- AMYLYHGYASWELD-UHFFFAOYSA-N 2-[4-(6-pyridin-4-yl-3-pyrrolidin-1-ylpyrazin-2-yl)piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C1=NC(C=2C=CN=CC=2)=CN=C1N1CCCC1 AMYLYHGYASWELD-UHFFFAOYSA-N 0.000 description 1
- FATWAIVJEMORGA-UHFFFAOYSA-N 2-[4-[3-(dimethylamino)-6-pyridin-4-ylpyrazin-2-yl]piperazin-1-yl]ethanol;hydrochloride Chemical compound Cl.CN(C)C1=NC=C(C=2C=CN=CC=2)N=C1N1CCN(CCO)CC1 FATWAIVJEMORGA-UHFFFAOYSA-N 0.000 description 1
- NAMYPXNPPPQOFV-UHFFFAOYSA-N 2-[4-[3-(dimethylamino)-6-trimethylstannylpyrazin-2-yl]piperazin-1-yl]ethanol Chemical compound CN(C)C1=NC=C([Sn](C)(C)C)N=C1N1CCN(CCO)CC1 NAMYPXNPPPQOFV-UHFFFAOYSA-N 0.000 description 1
- XMOYCKMWZZRNSJ-UHFFFAOYSA-N 2-[4-[6-bromo-3-(dimethylamino)pyrazin-2-yl]piperazin-1-yl]ethanol Chemical compound CN(C)C1=NC=C(Br)N=C1N1CCN(CCO)CC1 XMOYCKMWZZRNSJ-UHFFFAOYSA-N 0.000 description 1
- BFXKYURWGOIOKZ-UHFFFAOYSA-N 2-[[3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-yl]amino]ethanol;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1NCCO BFXKYURWGOIOKZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical class Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWWBJRWCIHWHPR-UHFFFAOYSA-N 2-chloro-4-[5-(dimethylamino)-6-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-yl]pyridine-3-carbaldehyde Chemical compound CN(C)C1=NC=C(C=2C(=C(Cl)N=CC=2)C=O)N=C1N1CCCN(C)CC1 FWWBJRWCIHWHPR-UHFFFAOYSA-N 0.000 description 1
- OPZCXONVRBYGHX-UHFFFAOYSA-N 2-chloro-4-iodopyridine-3-carbaldehyde Chemical compound ClC1=NC=CC(I)=C1C=O OPZCXONVRBYGHX-UHFFFAOYSA-N 0.000 description 1
- VKODNDVUXJZYBC-UHFFFAOYSA-N 2-n-methyl-3-n-piperidin-3-yl-5-pyridin-4-ylpyrazine-2,3-diamine;hydrochloride Chemical compound Cl.CNC1=NC=C(C=2C=CN=CC=2)N=C1NC1CCCNC1 VKODNDVUXJZYBC-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- FMPQINQOBNERLC-UHFFFAOYSA-N 2-piperidin-1-ylpyrazine Chemical compound C1CCCCN1C1=CN=CC=N1 FMPQINQOBNERLC-UHFFFAOYSA-N 0.000 description 1
- AYRDTTSXWWPDQA-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyrazine Chemical compound C1CCCN1C1=CN=CC=N1 AYRDTTSXWWPDQA-UHFFFAOYSA-N 0.000 description 1
- HGIZYQXNOWPPKQ-UHFFFAOYSA-N 3,5-dibromo-2-piperidin-1-ylpyrazine Chemical compound BrC1=NC(Br)=CN=C1N1CCCCC1 HGIZYQXNOWPPKQ-UHFFFAOYSA-N 0.000 description 1
- HSFHAJCNGVDNKN-UHFFFAOYSA-N 3,5-dibromo-2-pyrrolidin-1-ylpyrazine Chemical compound BrC1=NC(Br)=CN=C1N1CCCC1 HSFHAJCNGVDNKN-UHFFFAOYSA-N 0.000 description 1
- WGTPQLVSXKMUJE-UHFFFAOYSA-N 3,5-dibromo-n,n-diethylpyrazin-2-amine Chemical compound CCN(CC)C1=NC=C(Br)N=C1Br WGTPQLVSXKMUJE-UHFFFAOYSA-N 0.000 description 1
- VISVCQGIUUSOQY-UHFFFAOYSA-N 3,5-dibromo-n-(2-methoxyethyl)pyrazin-2-amine Chemical compound COCCNC1=NC=C(Br)N=C1Br VISVCQGIUUSOQY-UHFFFAOYSA-N 0.000 description 1
- AGAKWTWMAXDNJG-UHFFFAOYSA-N 3,5-dibromo-n-methylpyrazin-2-amine Chemical compound CNC1=NC=C(Br)N=C1Br AGAKWTWMAXDNJG-UHFFFAOYSA-N 0.000 description 1
- MBZQGZKEMHGLFL-UHFFFAOYSA-N 3-(1-methylpiperidin-3-yl)oxy-5-pyridin-4-ylpyrazin-2-amine Chemical compound C1N(C)CCCC1OC1=NC(C=2C=CN=CC=2)=CN=C1N MBZQGZKEMHGLFL-UHFFFAOYSA-N 0.000 description 1
- VICPBWUQYFGKDQ-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)oxy-5-pyridin-4-ylpyrazin-2-amine Chemical compound C1CN(C)CCC1OC1=NC(C=2C=CN=CC=2)=CN=C1N VICPBWUQYFGKDQ-UHFFFAOYSA-N 0.000 description 1
- AHHGBHXZBKHKCK-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-(1h-pyrazol-5-yl)pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C2=NNC=C2)=CN=C1N AHHGBHXZBKHKCK-UHFFFAOYSA-N 0.000 description 1
- FIMMIQXLCOONFY-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-[1-(2-trimethylsilylethoxymethyl)indazol-5-yl]pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C=2C=C3C=NN(COCC[Si](C)(C)C)C3=CC=2)=CN=C1N FIMMIQXLCOONFY-UHFFFAOYSA-N 0.000 description 1
- JMVWAHIKRGNCMC-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-[1-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C2=NN(COCC[Si](C)(C)C)C=C2)=CN=C1N JMVWAHIKRGNCMC-UHFFFAOYSA-N 0.000 description 1
- PBXFQCNUAUPBJC-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-[2-(2-trimethylsilylethoxymethyl)indazol-5-yl]pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C2=CC3=CN(COCC[Si](C)(C)C)N=C3C=C2)=CN=C1N PBXFQCNUAUPBJC-UHFFFAOYSA-N 0.000 description 1
- FYQYLLVRXYFIQR-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-[2-(2-trimethylsilylethoxymethyl)indazol-6-yl]pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C2=CC3=NN(COCC[Si](C)(C)C)C=C3C=C2)=CN=C1N FYQYLLVRXYFIQR-UHFFFAOYSA-N 0.000 description 1
- PIMQFHNTBSHECK-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1N PIMQFHNTBSHECK-UHFFFAOYSA-N 0.000 description 1
- ORKYGBNXLVVNJY-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-5-trimethylstannylpyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC([Sn](C)(C)C)=CN=C1N ORKYGBNXLVVNJY-UHFFFAOYSA-N 0.000 description 1
- QHGSHOFBCVGHGQ-UHFFFAOYSA-N 3-(azepan-1-yl)-n-piperidin-3-yl-6-pyridin-4-ylpyrazin-2-amine Chemical compound C1CCNCC1NC1=NC(C=2C=CN=CC=2)=CN=C1N1CCCCCC1 QHGSHOFBCVGHGQ-UHFFFAOYSA-N 0.000 description 1
- JTOHGXUJVJOALU-UHFFFAOYSA-N 3-[4-(3-amino-6-pyridin-4-ylpyrazin-2-yl)piperazin-1-yl]propan-1-ol Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1N1CCN(CCCO)CC1 JTOHGXUJVJOALU-UHFFFAOYSA-N 0.000 description 1
- LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 description 1
- AKVWVKHRZJYTNJ-UHFFFAOYSA-N 3-piperazin-1-yl-5-pyridin-4-ylpyrazin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1=NC=C(C=2C=CN=CC=2)N=C1N1CCNCC1 AKVWVKHRZJYTNJ-UHFFFAOYSA-N 0.000 description 1
- TZQVXPCPMMGDPH-UHFFFAOYSA-N 3-piperidin-1-yl-5-pyridin-4-ylpyrazin-2-amine Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1N1CCCCC1 TZQVXPCPMMGDPH-UHFFFAOYSA-N 0.000 description 1
- FJJQZOJBSPZJMP-UHFFFAOYSA-N 3-piperidin-1-yl-n-piperidin-3-yl-6-pyridin-4-ylpyrazin-2-amine Chemical compound C1CCCCN1C1=NC=C(C=2C=CN=CC=2)N=C1NC1CNCCC1 FJJQZOJBSPZJMP-UHFFFAOYSA-N 0.000 description 1
- LNLDXJFZFPDHEV-UHFFFAOYSA-N 3-piperidin-3-yloxy-5-pyridin-4-ylpyrazin-2-amine Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1OC1CCCNC1 LNLDXJFZFPDHEV-UHFFFAOYSA-N 0.000 description 1
- ORJABSJVKHTTMZ-UHFFFAOYSA-N 4-(3,5-dibromopyrazin-2-yl)morpholine Chemical compound BrC1=NC(Br)=CN=C1N1CCOCC1 ORJABSJVKHTTMZ-UHFFFAOYSA-N 0.000 description 1
- JHBQIJFVIMJSCB-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole;trimethyl-[2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]methoxy]ethyl]silane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1.O1C(C)(C)C(C)(C)OB1C1=CN(COCC[Si](C)(C)C)N=C1 JHBQIJFVIMJSCB-UHFFFAOYSA-N 0.000 description 1
- LEOCAYWQLNMVIZ-UHFFFAOYSA-N 4-[3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-yl]morpholine;trihydrochloride Chemical compound Cl.Cl.Cl.C1CN(C)CCCN1C1=NC(C=2C=CN=CC=2)=CN=C1N1CCOCC1 LEOCAYWQLNMVIZ-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- FFSZVTIOFCMLGM-UHFFFAOYSA-N 4-pyrazin-2-ylmorpholine Chemical compound C1COCCN1C1=CN=CC=N1 FFSZVTIOFCMLGM-UHFFFAOYSA-N 0.000 description 1
- BHEMXFWEUYIYGK-UHFFFAOYSA-N 5-(1h-indazol-4-yl)-3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(C=2C=3C=NNC=3C=CC=2)=CN=C1N BHEMXFWEUYIYGK-UHFFFAOYSA-N 0.000 description 1
- PPEZQOFQXOFBLW-UHFFFAOYSA-N 5-(1h-indazol-5-yl)-3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-amine;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCCN1C1=NC(C=2C=C3C=NNC3=CC=2)=CN=C1N PPEZQOFQXOFBLW-UHFFFAOYSA-N 0.000 description 1
- NNHVMTHRMJEYLY-UHFFFAOYSA-N 5-[6-(1,4-diazepan-1-yl)-5-pyrrolidin-1-ylpyrazin-2-yl]-1h-indazole;hydrochloride Chemical compound Cl.C1CCCN1C1=NC=C(C=2C=C3C=NNC3=CC=2)N=C1N1CCNCCC1 NNHVMTHRMJEYLY-UHFFFAOYSA-N 0.000 description 1
- FQEDEBIOMGGULK-UHFFFAOYSA-N 5-[6-(1,4-diazepan-1-yl)-5-pyrrolidin-1-ylpyrazin-2-yl]-3-methyl-2h-indazole;hydrochloride Chemical compound Cl.C1=C2C(C)=NNC2=CC=C1C(N=C1N2CCNCCC2)=CN=C1N1CCCC1 FQEDEBIOMGGULK-UHFFFAOYSA-N 0.000 description 1
- MMFGGDVQLQQQRX-UHFFFAOYSA-N 5-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C=C1C=O MMFGGDVQLQQQRX-UHFFFAOYSA-N 0.000 description 1
- MTGULOFJRGDTSK-UHFFFAOYSA-N 5-bromo-3-(1-methylpiperidin-3-yl)oxypyrazin-2-amine Chemical compound C1N(C)CCCC1OC1=NC(Br)=CN=C1N MTGULOFJRGDTSK-UHFFFAOYSA-N 0.000 description 1
- NIKNGYCPNMBIRS-UHFFFAOYSA-N 5-bromo-3-(1-methylpiperidin-4-yl)oxypyrazin-2-amine Chemical compound C1CN(C)CCC1OC1=NC(Br)=CN=C1N NIKNGYCPNMBIRS-UHFFFAOYSA-N 0.000 description 1
- LPKNKJFVNHRDAK-UHFFFAOYSA-N 5-bromo-3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-amine Chemical compound C1CN(C)CCCN1C1=NC(Br)=CN=C1N LPKNKJFVNHRDAK-UHFFFAOYSA-N 0.000 description 1
- NROSWDLLTJGGSD-UHFFFAOYSA-N 5-bromo-3-[3-(dimethylamino)propoxy]-n,n-dimethylpyrazin-2-amine Chemical compound CN(C)CCCOC1=NC(Br)=CN=C1N(C)C NROSWDLLTJGGSD-UHFFFAOYSA-N 0.000 description 1
- VXIPVAKTOSSGFF-UHFFFAOYSA-N 5-bromo-3-[4-(dimethylamino)piperidin-1-yl]pyrazin-2-amine Chemical compound C1CC(N(C)C)CCN1C1=NC(Br)=CN=C1N VXIPVAKTOSSGFF-UHFFFAOYSA-N 0.000 description 1
- XDJNHYAQZWCIAH-UHFFFAOYSA-N 5-bromo-3-methyl-2h-indazole Chemical compound C1=CC(Br)=CC2=C(C)NN=C21 XDJNHYAQZWCIAH-UHFFFAOYSA-N 0.000 description 1
- NZOWLAWUDIBPOS-UHFFFAOYSA-N 5-bromo-3-n-(1-methylpiperidin-3-yl)pyrazine-2,3-diamine Chemical compound C1N(C)CCCC1NC1=NC(Br)=CN=C1N NZOWLAWUDIBPOS-UHFFFAOYSA-N 0.000 description 1
- AOSKFCCYVNIUEF-UHFFFAOYSA-N 5-bromo-3-n-(1-methylpiperidin-4-yl)pyrazine-2,3-diamine Chemical compound C1CN(C)CCC1NC1=NC(Br)=CN=C1N AOSKFCCYVNIUEF-UHFFFAOYSA-N 0.000 description 1
- BSLRGJPOLCWVNC-UHFFFAOYSA-N 5-bromo-3-n-methyl-3-n-(1-methylpiperidin-4-yl)pyrazine-2,3-diamine Chemical compound N=1C(Br)=CN=C(N)C=1N(C)C1CCN(C)CC1 BSLRGJPOLCWVNC-UHFFFAOYSA-N 0.000 description 1
- DBDDXXRVBFTQQY-UHFFFAOYSA-N 5-bromo-n-methyl-3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-amine Chemical compound CNC1=NC=C(Br)N=C1N1CCN(C)CCC1 DBDDXXRVBFTQQY-UHFFFAOYSA-N 0.000 description 1
- CPYAUFLEMLTQAA-UHFFFAOYSA-N 5-bromopyrazine-2,3-diamine Chemical compound NC1=NC=C(Br)N=C1N CPYAUFLEMLTQAA-UHFFFAOYSA-N 0.000 description 1
- QKTLQTJDJLKBGE-UHFFFAOYSA-N 5-pyridin-4-yl-3-n-pyrrolidin-3-ylpyrazine-2,3-diamine Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1NC1CCNC1 QKTLQTJDJLKBGE-UHFFFAOYSA-N 0.000 description 1
- WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 101100071588 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HSP12 gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102000018410 Small GTPase Rho Human genes 0.000 description 1
- 108050007506 Small GTPase Rho Proteins 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 1
- AUOJXGNOXVDGQG-UHFFFAOYSA-N [1-(3-amino-6-bromopyrazin-2-yl)piperidin-4-yl]methanol Chemical compound NC1=NC=C(Br)N=C1N1CCC(CO)CC1 AUOJXGNOXVDGQG-UHFFFAOYSA-N 0.000 description 1
- AOUCCFLOSJCLER-UHFFFAOYSA-N [1-(3-amino-6-pyridin-4-ylpyrazin-2-yl)piperidin-4-yl]methanol Chemical compound NC1=NC=C(C=2C=CN=CC=2)N=C1N1CCC(CO)CC1 AOUCCFLOSJCLER-UHFFFAOYSA-N 0.000 description 1
- NUKNSMBCVKGDOM-UHFFFAOYSA-M [Br-].[Mg+]C.CC(O)C1=CC(Br)=CC=C1F Chemical compound [Br-].[Mg+]C.CC(O)C1=CC(Br)=CC=C1F NUKNSMBCVKGDOM-UHFFFAOYSA-M 0.000 description 1
- FQOPHKQSBCEBMJ-UHFFFAOYSA-N [O--].[O--].[O--].[Cr+6].CC(=O)c1cc(Br)ccc1F Chemical compound [O--].[O--].[O--].[Cr+6].CC(=O)c1cc(Br)ccc1F FQOPHKQSBCEBMJ-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- LBOVMDOAMWYGHK-UHFFFAOYSA-N ethanol;methylsulfinylmethane Chemical compound CCO.CS(C)=O LBOVMDOAMWYGHK-UHFFFAOYSA-N 0.000 description 1
- MUFHMSXLAXIORY-UHFFFAOYSA-N ethyl 4-[(3-amino-6-bromopyrazin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC(Br)=CN=C1N MUFHMSXLAXIORY-UHFFFAOYSA-N 0.000 description 1
- GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- LUOGVMPUQUBQTC-UHFFFAOYSA-N hydron;1-methylpiperidin-3-amine;dichloride Chemical compound Cl.Cl.CN1CCCC(N)C1 LUOGVMPUQUBQTC-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical class C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
- GZZCYMXZJQCAJU-UHFFFAOYSA-N isoquinoline-1-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)=NC=CC2=C1 GZZCYMXZJQCAJU-UHFFFAOYSA-N 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- PZVIQJUYCPIZDK-UHFFFAOYSA-N methyl 4-[5-amino-6-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(C=2N=C(C(N)=NC=2)N2CCN(C)CCC2)=C1 PZVIQJUYCPIZDK-UHFFFAOYSA-N 0.000 description 1
- VTENWIPSWAMPKI-UHFFFAOYSA-N methyl 4-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=CC(Cl)=CC=N1 VTENWIPSWAMPKI-UHFFFAOYSA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- XRYGCVVVDCEPRL-UHFFFAOYSA-N n,1-dimethylpiperidin-4-amine Chemical compound CNC1CCN(C)CC1 XRYGCVVVDCEPRL-UHFFFAOYSA-N 0.000 description 1
- OHYDSLAPKVEIDI-UHFFFAOYSA-N n,n-diethyl-3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-amine;hydrochloride Chemical compound Cl.CCN(CC)C1=NC=C(C=2C=CN=CC=2)N=C1N1CCCN(C)CC1 OHYDSLAPKVEIDI-UHFFFAOYSA-N 0.000 description 1
- KDOFSJLDQIBHBT-UHFFFAOYSA-N n,n-dimethyl-3-(4-methyl-1,4-diazepan-1-yl)-5-trimethylstannylpyrazin-2-amine Chemical compound CN(C)C1=NC=C([Sn](C)(C)C)N=C1N1CCN(C)CCC1 KDOFSJLDQIBHBT-UHFFFAOYSA-N 0.000 description 1
- XCYYHIWBJXVEDC-UHFFFAOYSA-N n,n-dimethyl-3-piperidin-4-yloxy-5-pyridin-4-ylpyrazin-2-amine;hydrochloride Chemical compound Cl.CN(C)C1=NC=C(C=2C=CN=CC=2)N=C1OC1CCNCC1 XCYYHIWBJXVEDC-UHFFFAOYSA-N 0.000 description 1
- ZUULZFKZCLLJAH-UHFFFAOYSA-N n-(2-methoxyethyl)-3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-amine;hydrochloride Chemical compound Cl.COCCNC1=NC=C(C=2C=CN=CC=2)N=C1N1CCCN(C)CC1 ZUULZFKZCLLJAH-UHFFFAOYSA-N 0.000 description 1
- OPDWWJJAPJOEJK-UHFFFAOYSA-N n-(2-methoxyethyl)-n-methyl-3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-amine;hydrochloride Chemical compound Cl.COCCN(C)C1=NC=C(C=2C=CN=CC=2)N=C1N1CCCN(C)CC1 OPDWWJJAPJOEJK-UHFFFAOYSA-N 0.000 description 1
- SQHNPLCTJPREES-UHFFFAOYSA-N n-(2-methoxyethyl)pyrazin-2-amine Chemical compound COCCNC1=CN=CC=N1 SQHNPLCTJPREES-UHFFFAOYSA-N 0.000 description 1
- SPPMYEZUXAGJFN-UHFFFAOYSA-N n-methyl-3-(4-methyl-1,4-diazepan-1-yl)-5-pyridin-4-ylpyrazin-2-amine;hydrochloride Chemical compound Cl.CNC1=NC=C(C=2C=CN=CC=2)N=C1N1CCCN(C)CC1 SPPMYEZUXAGJFN-UHFFFAOYSA-N 0.000 description 1
- VGKOARVVEXZTPU-UHFFFAOYSA-N n-methylpyrazin-2-amine Chemical compound CNC1=CN=CC=N1 VGKOARVVEXZTPU-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- LJGKDXPEWNIRIJ-UHFFFAOYSA-N tert-butyl 3-(3-amino-6-bromopyrazin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1OC1=NC(Br)=CN=C1N LJGKDXPEWNIRIJ-UHFFFAOYSA-N 0.000 description 1
- INYQIBMHNZXKAC-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-bromopyrazin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1NC1=NC(Br)=CN=C1N INYQIBMHNZXKAC-UHFFFAOYSA-N 0.000 description 1
- GSRKNXSYCQWKHR-UHFFFAOYSA-N tert-butyl 3-[[6-bromo-3-(methylamino)pyrazin-2-yl]amino]piperidine-1-carboxylate Chemical compound CNC1=NC=C(Br)N=C1NC1CN(C(=O)OC(C)(C)C)CCC1 GSRKNXSYCQWKHR-UHFFFAOYSA-N 0.000 description 1
- KEKKOBDBXZTFAR-UHFFFAOYSA-N tert-butyl 3-aminopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(N)C1 KEKKOBDBXZTFAR-UHFFFAOYSA-N 0.000 description 1
- CMIBWIAICVBURI-UHFFFAOYSA-N tert-butyl 3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C1 CMIBWIAICVBURI-UHFFFAOYSA-N 0.000 description 1
- GYGPECZTFLDDGC-UHFFFAOYSA-N tert-butyl 4-[3-(dimethylamino)-6-pyridin-4-ylpyrazin-2-yl]oxypiperidine-1-carboxylate Chemical compound CN(C)C1=NC=C(C=2C=CN=CC=2)N=C1OC1CCN(C(=O)OC(C)(C)C)CC1 GYGPECZTFLDDGC-UHFFFAOYSA-N 0.000 description 1
- IHLHLSHVPNKJJV-UHFFFAOYSA-N tert-butyl 4-[3-pyrrolidin-1-yl-6-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazin-2-yl]-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1C1=NC(C=2C=3C=CNC=3N=CC=2)=CN=C1N1CCCC1 IHLHLSHVPNKJJV-UHFFFAOYSA-N 0.000 description 1
- AJZGPOJYEPOCSX-UHFFFAOYSA-N tert-butyl 4-[3-pyrrolidin-1-yl-6-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC(C=2C=3C=CNC=3N=CC=2)=CN=C1N1CCCC1 AJZGPOJYEPOCSX-UHFFFAOYSA-N 0.000 description 1
- LRKAOOWXRGEEHQ-UHFFFAOYSA-N tert-butyl 4-[6-(1h-indazol-5-yl)-3-pyrrolidin-1-ylpyrazin-2-yl]-1,4-diazepane-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN1C1=NC(C=2C=C3C=NNC3=CC=2)=CN=C1N1CCCC1 LRKAOOWXRGEEHQ-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LFQAIZQRBGNODB-UHFFFAOYSA-N trimethyl-[6-(4-methyl-1,4-diazepan-1-yl)-5-pyrrolidin-1-ylpyrazin-2-yl]stannane Chemical compound C1CN(C)CCCN1C1=NC([Sn](C)(C)C)=CN=C1N1CCCC1 LFQAIZQRBGNODB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63938904P | 2004-12-27 | 2004-12-27 | |
| US60/639,389 | 2004-12-27 | ||
| PCT/US2005/045384 WO2006071548A2 (en) | 2004-12-27 | 2005-12-14 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2590261A1 CA2590261A1 (en) | 2006-07-06 |
| CA2590261C true CA2590261C (en) | 2011-08-16 |
Family
ID=36615388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2590261A Expired - Fee Related CA2590261C (en) | 2004-12-27 | 2005-12-14 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080269249A2 (enExample) |
| EP (1) | EP1830853B1 (enExample) |
| JP (1) | JP2008525453A (enExample) |
| KR (1) | KR100994173B1 (enExample) |
| CN (1) | CN101102773B (enExample) |
| AR (1) | AR053110A1 (enExample) |
| AT (1) | ATE519488T1 (enExample) |
| AU (1) | AU2005322338B2 (enExample) |
| BR (1) | BRPI0519508A2 (enExample) |
| CA (1) | CA2590261C (enExample) |
| ES (1) | ES2368338T3 (enExample) |
| MX (1) | MX2007007797A (enExample) |
| PL (1) | PL383491A1 (enExample) |
| TW (1) | TW200633709A (enExample) |
| WO (1) | WO2006071548A2 (enExample) |
| ZA (1) | ZA200704959B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| CN101340912A (zh) * | 2005-12-22 | 2009-01-07 | 爱尔康研究有限公司 | 用于治疗rho激酶介导的疾病和病状的(吲唑-5-基)-吡嗪和(1,3-二氢-吲哚-2-酮)-吡嗪 |
| WO2007126964A2 (en) * | 2006-03-31 | 2007-11-08 | Schering Corporation | Kinase inhibitors |
| US20080021217A1 (en) * | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
| KR20090071612A (ko) | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| US7825261B2 (en) * | 2006-12-05 | 2010-11-02 | National Taiwan University | Indazole compounds |
| SG182187A1 (en) * | 2007-06-08 | 2012-07-30 | Abbott Gmbh & Co Kg | 5-heteroaryl substituted indazoles as kinase inhibitors |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| EP2376485B1 (en) | 2008-12-19 | 2017-12-06 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
| AU2010313397B2 (en) * | 2009-10-30 | 2015-07-02 | Janssen Pharmaceutica Nv | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| AU2010313401B2 (en) * | 2009-10-30 | 2015-07-23 | Janssen Pharmaceutica Nv | Pyrimidine compounds as delta opioid receptor modulators |
| CN102791703B (zh) * | 2009-10-30 | 2014-07-09 | 詹森药业有限公司 | 用作δ阿片类受体调节剂的吡嗪 |
| EP2569286B1 (en) * | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| AU2011253021A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| KR20130066633A (ko) | 2010-05-12 | 2013-06-20 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| KR102056586B1 (ko) | 2011-09-30 | 2019-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료 |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| BR112014007721B1 (pt) | 2011-09-30 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | Processos para preparar compostos úteis como inibidores de atr quinase |
| EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| KR101504722B1 (ko) | 2013-06-12 | 2015-03-24 | 한국화학연구원 | 카모로놀 화합물을 유효성분으로 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물 |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| GB201715410D0 (en) | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| WO2019119207A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6271224B1 (en) * | 1995-12-21 | 2001-08-07 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| US5798380A (en) * | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| BR9711154A (pt) * | 1996-08-12 | 1999-08-17 | Yoshitomi Pharmaceutical | Agente farmac-utico contendo inibidor cinase rho |
| US6673812B1 (en) * | 1998-08-17 | 2004-01-06 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
| DE60045890D1 (de) * | 1999-04-27 | 2011-06-09 | Mitsubishi Tanabe Pharma Corp | Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen |
| US6348494B1 (en) * | 2000-11-21 | 2002-02-19 | American Home Products Corporation | Ethers of o-desmethyl venlafaxine |
| ATE327993T1 (de) * | 2000-03-16 | 2006-06-15 | Mitsubishi Pharma Corp | Amid-verbindung und deren verwendung |
| AU2001236006A1 (en) * | 2000-03-31 | 2001-10-15 | Mitsubishi Pharma Corporation | Preventives/remedies for kidney diseases |
| JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| MXPA04004714A (es) * | 2001-11-21 | 2004-08-19 | Upjohn Co | Derivados de aril 1,4-pirazina sustituidos. |
| AU2002358390A1 (en) | 2001-12-18 | 2003-06-30 | Astrazeneca Ab | Novel compounds |
| US7094789B2 (en) * | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
| CA2496197A1 (en) * | 2002-08-20 | 2004-03-04 | Neurogen Corporation | 5-substituted-2-arylpyrazines as modulators of crf receptors |
| GB0219746D0 (en) * | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
| CN101468965A (zh) * | 2003-03-24 | 2009-07-01 | 默克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
| GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| EP1678160A1 (en) * | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| WO2005058876A1 (en) * | 2003-12-16 | 2005-06-30 | Gpc Biotech Ag | Pyrazine derivatives as effective compounds against infectious diseases |
| WO2005095384A1 (en) * | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
-
2005
- 2005-12-14 CA CA2590261A patent/CA2590261C/en not_active Expired - Fee Related
- 2005-12-14 EP EP05854156A patent/EP1830853B1/en not_active Expired - Lifetime
- 2005-12-14 MX MX2007007797A patent/MX2007007797A/es active IP Right Grant
- 2005-12-14 PL PL383491A patent/PL383491A1/pl not_active Application Discontinuation
- 2005-12-14 ZA ZA200704959A patent/ZA200704959B/xx unknown
- 2005-12-14 CN CN200580046786XA patent/CN101102773B/zh not_active Expired - Fee Related
- 2005-12-14 ES ES05854156T patent/ES2368338T3/es not_active Expired - Lifetime
- 2005-12-14 WO PCT/US2005/045384 patent/WO2006071548A2/en not_active Ceased
- 2005-12-14 AT AT05854156T patent/ATE519488T1/de not_active IP Right Cessation
- 2005-12-14 US US11/302,825 patent/US20080269249A2/en not_active Abandoned
- 2005-12-14 AU AU2005322338A patent/AU2005322338B2/en not_active Ceased
- 2005-12-14 KR KR1020077017035A patent/KR100994173B1/ko not_active Expired - Fee Related
- 2005-12-14 JP JP2007548311A patent/JP2008525453A/ja active Pending
- 2005-12-14 BR BRPI0519508-0A patent/BRPI0519508A2/pt not_active IP Right Cessation
- 2005-12-23 TW TW094146211A patent/TW200633709A/zh unknown
- 2005-12-26 AR ARP050105535A patent/AR053110A1/es not_active Application Discontinuation
-
2010
- 2010-05-05 US US12/774,399 patent/US20100216777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100216777A1 (en) | 2010-08-26 |
| WO2006071548A3 (en) | 2006-09-08 |
| CN101102773A (zh) | 2008-01-09 |
| ZA200704959B (en) | 2009-04-29 |
| EP1830853B1 (en) | 2011-08-10 |
| PL383491A1 (pl) | 2008-03-17 |
| AU2005322338B2 (en) | 2011-06-09 |
| CA2590261A1 (en) | 2006-07-06 |
| US20080269249A2 (en) | 2008-10-30 |
| BRPI0519508A2 (pt) | 2009-03-17 |
| US20060142307A1 (en) | 2006-06-29 |
| WO2006071548A2 (en) | 2006-07-06 |
| KR100994173B1 (ko) | 2010-11-15 |
| HK1104222A1 (en) | 2008-01-11 |
| KR20070100952A (ko) | 2007-10-15 |
| JP2008525453A (ja) | 2008-07-17 |
| AU2005322338A1 (en) | 2006-07-06 |
| ES2368338T3 (es) | 2011-11-16 |
| EP1830853A2 (en) | 2007-09-12 |
| MX2007007797A (es) | 2007-08-23 |
| TW200633709A (en) | 2006-10-01 |
| AR053110A1 (es) | 2007-04-25 |
| CN101102773B (zh) | 2010-10-27 |
| ATE519488T1 (de) | 2011-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2590261C (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
| US10463651B2 (en) | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | |
| EP3035800B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| US10350199B2 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| EP3009431B1 (en) | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer | |
| EP3190889B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN104428293B (zh) | 调节TNFα的苯并咪唑类 | |
| KR20220066922A (ko) | Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 | |
| WO2017023986A1 (en) | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof | |
| CN106232597B (zh) | 原肌球蛋白相关激酶(trk)抑制剂 | |
| BR112020015328A2 (pt) | Inibidores de gcn2 e usos dos mesmos | |
| BR112020013759A2 (pt) | triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho | |
| WO2017024013A1 (en) | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| BR112012002854B1 (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica e uso dos mesmos | |
| CN110156813A (zh) | 作为trk抑制剂的杂环化合物 | |
| JP2015523402A (ja) | タンパク質キナーゼ阻害薬 | |
| WO2020150545A1 (en) | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway | |
| KR20150133765A (ko) | 거대고리 rip2 키나제 억제제 | |
| US11981658B2 (en) | Substituted aminopyridine compounds as EGFR inhibitors | |
| CA3183214A1 (en) | Condensed ring compounds that inhibit h-pgds | |
| HK1104222B (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| KR20130119846A (ko) | 신규 인다졸 유도체 또는 그의 염 및 그 제조 중간체와, 그것을 이용한 항산화제, 인다졸 유도체 또는 그의 염의 용도 | |
| HK40082765A (en) | 2-(2,4,5-substituted-anilino)pyrimidine compounds as egfr modulators | |
| CN121226329A (zh) | 一种治疗或预防lrrk2介导的疾病的化合物 | |
| CN116354894A (zh) | 取代的哌嗪类化合物及其在药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131216 |